|
US2018280403A1
|
|
Compositions and methods relating to the radioprotective effects of apilimod
|
|
CN110536702A
|
|
Use the method for HSP90 inhibitor for treating cancer
|
|
US2018050041A1
|
|
Compositions and Methods for Treating Niemann Pick C Disease
|
|
US2018036420A1
|
|
Methods for enhancing the delivery of molecules across the blood brain barrier
|
|
EP3405199A1
|
|
Biomarkers for treating cancer with apilimod
|
|
TW201717957A
|
|
Methods for treating cancer using apilimod
|
|
WO2016130645A1
|
|
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
EP3253389A1
|
|
Apilimod compositions and methods for using same
|
|
US2018078561A1
|
|
Active metabolites of apilimod and uses thereof
|
|
CA2966356A1
|
|
Apilimod for use in the treatment of melanoma
|
|
BR112017008799A2
|
|
apilimod compositions and methods of use in treating kidney cancer
|
|
CN107249576A
|
|
Inhalable rapamycin formulation for treating pulmonary hypertension
|
|
WO2016003886A1
|
|
4-aminoquinoline compositions and methods for using same
|
|
KR20160120739A
|
|
Rapamycin for the Treatment of Lymphangioleiomyomatosis
|
|
US2017007613A1
|
|
Apilimod compositions and methods for using same
|
|
MX2016009243A
|
|
Mutagenesis methods.
|
|
CA2926719A1
|
|
Rapamycin for the treatment of lymphangioleiomyomatosis
|
